These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15904514)

  • 1. A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial.
    Yang J; Acosta CJ; Si GA; Zeng J; Li CY; Liang DB; Ochiai RL; Page AL; Danovaro-Holliday MC; Zhang J; Zhou BD; Liao HZ; Wang ML; Tan DM; Tang ZZ; Gong J; Park JK; Ali M; Ivanoff B; Liang GC; Yang HH; Pang T; Xu ZY; Donner A; Galindo CM; Dong BQ; Clemens JD
    BMC Public Health; 2005 May; 5():49. PubMed ID: 15904514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform.
    Agtini MD; Ochiai RL; Soeharno R; Lee HJ; Sundoro J; Hadinegoro SR; Han OP; Tana L; Halim FX; Ghani L; Delima ; Lestari W; Sintawati FX; Kusumawardani N; Malik R; Santoso TS; Nadjib M; Soeroso S; Wangsasaputra F; Ali M; Ivanoff B; Galindo CM; Pang T; Clemens JD; Suwandono A; Acosta CJ
    Public Health; 2006 Nov; 120(11):1081-7. PubMed ID: 17005220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The feasibility of a school-based VI polysaccharide vaccine mass immunization campaign in Hue City, central Vietnam: streamlining a typhoid fever preventive strategy.
    Thiem VD; Danovaro-Holliday MC; Canh DG; Son ND; Hoa NT; Thuy DT; Ochiai RL; Lan NT; Hop TQ; Ali M; Park JK; Abu-Elyazeed R; Holliday K; Ivanoff B; Anh DD; Pang T; Donner A; Galindo CM; Trach DD; Clemens JD; Acosta CJ
    Southeast Asian J Trop Med Public Health; 2006 May; 37(3):515-22. PubMed ID: 17120972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
    Zhou WZ; Koo HW; Wang XY; Zhang J; Park JK; Zhu F; Deen J; Acosta CJ; Chen Y; Wang H; Galindo CM; Ochiai L; Park T; von Seidlein L; Xu ZY; Clemens JD
    Pediatr Infect Dis J; 2007 Nov; 26(11):1001-5. PubMed ID: 17984806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan.
    Khan MI; Soofi SB; Ochiai RL; Habib MA; Sahito SM; Nizami SQ; Acosta CJ; Clemens JD; Bhutta ZA;
    Vaccine; 2012 Aug; 30(36):5389-95. PubMed ID: 22721899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
    Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
    Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China.
    Yang HH; Wu CG; Xie GZ; Gu QW; Wang BR; Wang LY; Wang HF; Ding ZS; Yang Y; Tan WS; Wang WY; Wang XC; Qin M; Wang JH; Tang HA; Jiang XM; Li YH; Wang ML; Zhang SL; Li GL
    Bull World Health Organ; 2001; 79(7):625-31. PubMed ID: 11477965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
    Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Japanese study to assess immunogenicity and safety of a typhoid Vi polysaccharide vaccine.
    Miyazu M; Kikuchi H; Hamada A; Fukushima S; Ouchi K; Bosch Castells V; Mihara H; Bonnet MC
    Vaccine; 2015 Nov; 33(48):6697-702. PubMed ID: 26518404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines for preventing typhoid fever.
    Anwar E; Goldberg E; Fraser A; Acosta CJ; Paul M; Leibovici L
    Cochrane Database Syst Rev; 2014 Jan; (1):CD001261. PubMed ID: 24385413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
    Patel PD; Patel P; Liang Y; Meiring JE; Misiri T; Mwakiseghile F; Tracy JK; Masesa C; Msuku H; Banda D; Mbewe M; Henrion M; Adetunji F; Simiyu K; Rotrosen E; Birkhold M; Nampota N; Nyirenda OM; Kotloff K; Gmeiner M; Dube Q; Kawalazira G; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM;
    N Engl J Med; 2021 Sep; 385(12):1104-1115. PubMed ID: 34525285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
    Sur D; Ochiai RL; Bhattacharya SK; Ganguly NK; Ali M; Manna B; Dutta S; Donner A; Kanungo S; Park JK; Puri MK; Kim DR; Dutta D; Bhaduri B; Acosta CJ; Clemens JD
    N Engl J Med; 2009 Jul; 361(4):335-44. PubMed ID: 19625715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
    Klugman KP; Gilbertson IT; Koornhof HJ; Robbins JB; Schneerson R; Schulz D; Cadoz M; Armand J
    Lancet; 1987 Nov; 2(8569):1165-9. PubMed ID: 2890805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
    J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of cluster randomization method on typhoid Vi vaccine trails].
    Dong BQ; Yang J; Tang ZZ; Yang HH; Zeng J; Zhang J; Wang ML; Liang GC; Si GA; Li CY; Liang DB; Liao HZ; Ochiai RL; Mohammad A; Acosta CJ; Clemens J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Feb; 26(2):97-100. PubMed ID: 15921608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Vi vaccination on spatial patterns of typhoid fever in the slums of Kolkata, India.
    Ali M; Sur D; Kim DR; Kanungo S; Bhattacharya SK; Manna B; Ochiai RL; Clemens J
    Vaccine; 2011 Nov; 29(48):9051-6. PubMed ID: 21939716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
    Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.